Cardioxyl previously completed a Phase IIa dose-defining study to evaluate the hemodynamic effects, safety and tolerability of CXL-1020, its initial nitroxyl (HNO) donor clinical candidate, in patients with acute decompensated heart failure (NCT01096043). Prior to that study, the company concluded a Phase I/IIa Dose-Escalation Study evaluating the safety and tolerability of CXL-1020 and specific effects on electrocardiographic and non-invasive hemodynamic parameters in patients with chronic heart failure (NCT01092325). More information is available on ClinicalTrials.gov. Having demonstrated human proof of concept with its first-generation compound, Cardioxyl has now advanced its improved second-generation HNO donor, CXL-1427, into the clinic. The first Phase I trial with CXL-1427 was initiated in February 2014.